AY20 Stock Overview
A pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Aytu BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.28 |
| 52 Week High | US$20.00 |
| 52 Week Low | US$2.89 |
| Beta | -0.41 |
| 1 Month Change | 0% |
| 3 Month Change | 1,504.21% |
| 1 Year Change | -81.83% |
| 3 Year Change | -98.71% |
| 5 Year Change | n/a |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| AY20 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -2.0% |
| 1Y | -81.8% | -15.6% | 6.9% |
Return vs Industry: AY20 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: AY20 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| AY20 volatility | |
|---|---|
| AY20 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AY20's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine AY20's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 164 | Josh Disbrow | aytubio.com |
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency.
Aytu BioPharma, Inc. Fundamentals Summary
| AY20 fundamental statistics | |
|---|---|
| Market cap | €7.66m |
| Earnings (TTM) | -€71.67m |
| Revenue (TTM) | €96.81m |
0.1x
P/S Ratio-0.1x
P/E RatioIs AY20 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AY20 income statement (TTM) | |
|---|---|
| Revenue | US$105.58m |
| Cost of Revenue | US$42.73m |
| Gross Profit | US$62.85m |
| Other Expenses | US$141.02m |
| Earnings | -US$78.17m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -20.69 |
| Gross Margin | 59.53% |
| Net Profit Margin | -74.04% |
| Debt/Equity Ratio | 47.8% |
How did AY20 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/08 01:07 |
| End of Day Share Price | 2023/01/10 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aytu BioPharma, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jennifer Kim | Cantor Fitzgerald & Co. |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| Nazibur Rahman | Maxim Group |